Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.